Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies
Background: Botulinum toxin-A is a well-established treatment for adult and pediatric spastic paresis and cervical dystonia. While guidelines and approved labels indicate that treatment should not occur more frequently than every 12 weeks, studies and real-world evidence show that the timing of symp...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.576117/full |
id |
doaj-398bad40c1e44ce59d3e1fa19a5adae1 |
---|---|
record_format |
Article |
spelling |
doaj-398bad40c1e44ce59d3e1fa19a5adae12020-11-25T03:32:23ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-09-011110.3389/fneur.2020.576117576117Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical StudiesAlberto Esquenazi0Mauricio R. Delgado1Robert A. Hauser2Philippe Picaut3Keith Foster4Andreas Lysandropoulos5Jean-Michel Gracies6Department of Physical Medicine and Rehabilitation, MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, United StatesNeurology and Neurotherapeutics Department, University of Texas Southwestern Medical Center and Scottish Rite Hospital for Children, Dallas, TX, United StatesUniversity of South Florida Parkinson's Disease and Movement Disorders Center of Excellence, Tampa, FL, United StatesIpsen Pharma, Cambridge, MA, United StatesIpsen Bioinnovation, Abingdon, United KingdomIpsen, Boulogne-Billancourt, FranceUR 7377, Université Paris-Est Créteil, Service de Rééducation Neurolocomotrice, Albert Chenevier-Henri Mondor Hospital, Créteil, FranceBackground: Botulinum toxin-A is a well-established treatment for adult and pediatric spastic paresis and cervical dystonia. While guidelines and approved labels indicate that treatment should not occur more frequently than every 12 weeks, studies and real-world evidence show that the timing of symptom recurrence between treatments may vary.Methods: We report retreatment criteria and response duration (retreatment intervals) from four pivotal, double-blind, placebo-controlled studies with open-label extensions involving patients treated with abobotulinumtoxinA (aboBoNTA) for upper limb (NCT01313299) or lower limb (NCT01249404) spastic paresis in adults, lower limb spastic paresis in children (NCT01249417), and cervical dystonia in adults (NCT00257660). We review results in light of recently available preclinical data.Results: In spastic paresis, 24.0–36.9% of upper limb patients treated with aboBoNTA and 20.1–32.0% of lower limb patients did not require retreatment before 16 weeks. Moreover, 72.8–93.8% of aboBoNTA-treated pediatric patients with lower limb spastic paresis did not require retreatment before 16 weeks (17.7–54.0% did not require retreatment before 28 weeks). In aboBoNTA-treated patients with cervical dystonia, 72.6–81.5% did not require retreatment before 16 weeks.Conclusion: AboBoNTA, when dosed as recommended, offers symptom relief beyond 12 weeks to many patients with spastic paresis and cervical dystonia. From recently available preclinical research, the amount of active neurotoxin administered with aboBoNTA might be a factor in explaining this long duration of response.https://www.frontiersin.org/article/10.3389/fneur.2020.576117/fullabobotulinumtoxinAbotulinum toxin-Aduration of responsespasticitycervical dystoniatreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alberto Esquenazi Mauricio R. Delgado Robert A. Hauser Philippe Picaut Keith Foster Andreas Lysandropoulos Jean-Michel Gracies |
spellingShingle |
Alberto Esquenazi Mauricio R. Delgado Robert A. Hauser Philippe Picaut Keith Foster Andreas Lysandropoulos Jean-Michel Gracies Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies Frontiers in Neurology abobotulinumtoxinA botulinum toxin-A duration of response spasticity cervical dystonia treatment |
author_facet |
Alberto Esquenazi Mauricio R. Delgado Robert A. Hauser Philippe Picaut Keith Foster Andreas Lysandropoulos Jean-Michel Gracies |
author_sort |
Alberto Esquenazi |
title |
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies |
title_short |
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies |
title_full |
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies |
title_fullStr |
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies |
title_full_unstemmed |
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies |
title_sort |
duration of symptom relief between injections for abobotulinumtoxina (dysport®) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2020-09-01 |
description |
Background: Botulinum toxin-A is a well-established treatment for adult and pediatric spastic paresis and cervical dystonia. While guidelines and approved labels indicate that treatment should not occur more frequently than every 12 weeks, studies and real-world evidence show that the timing of symptom recurrence between treatments may vary.Methods: We report retreatment criteria and response duration (retreatment intervals) from four pivotal, double-blind, placebo-controlled studies with open-label extensions involving patients treated with abobotulinumtoxinA (aboBoNTA) for upper limb (NCT01313299) or lower limb (NCT01249404) spastic paresis in adults, lower limb spastic paresis in children (NCT01249417), and cervical dystonia in adults (NCT00257660). We review results in light of recently available preclinical data.Results: In spastic paresis, 24.0–36.9% of upper limb patients treated with aboBoNTA and 20.1–32.0% of lower limb patients did not require retreatment before 16 weeks. Moreover, 72.8–93.8% of aboBoNTA-treated pediatric patients with lower limb spastic paresis did not require retreatment before 16 weeks (17.7–54.0% did not require retreatment before 28 weeks). In aboBoNTA-treated patients with cervical dystonia, 72.6–81.5% did not require retreatment before 16 weeks.Conclusion: AboBoNTA, when dosed as recommended, offers symptom relief beyond 12 weeks to many patients with spastic paresis and cervical dystonia. From recently available preclinical research, the amount of active neurotoxin administered with aboBoNTA might be a factor in explaining this long duration of response. |
topic |
abobotulinumtoxinA botulinum toxin-A duration of response spasticity cervical dystonia treatment |
url |
https://www.frontiersin.org/article/10.3389/fneur.2020.576117/full |
work_keys_str_mv |
AT albertoesquenazi durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT mauriciordelgado durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT robertahauser durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT philippepicaut durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT keithfoster durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT andreaslysandropoulos durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies AT jeanmichelgracies durationofsymptomreliefbetweeninjectionsforabobotulinumtoxinadysportinspasticparesisandcervicaldystoniacomparisonofevidencefromclinicalstudies |
_version_ |
1724568652857999360 |